A company in the Netherlands is building a bridge across a canal in Amsterdam using 3D-printing robots.

It seems that such attention-grabbing headlines appear regularly to declare how 3D-printing is destined to revolutionize manufacturing of all kinds. If the idea that key manufacturing products such as cars, aircraft – or indeed bridges – built by 3D printing sounds like hype, you’re mistaken.

The sex lives of older people have received a lot of attention recently. From the Netflix sitcom Grace and Frankie, which stars Jane Fonda and Lily Tomlin (both in their 70s) and does not shy away from the issue of sex, to the Channel 4 series that focused on “love and sex when we’re over 60”, it seems there is no escaping the message that older adults have and enjoy sex.

Every president for more than 30 years has required executive branch agencies to analyze regulatory impacts before issuing new requirements.

They’ve relied on the Office of Information and Regulatory Affairs (OIRA) in the Office of Management and Budget to review significant new rules to ensure the quality of such regulatory analysis.

The recent commitments by the leaders of G7 nations to reduce emissions of carbon dioxide to 40-70% below current levels by 2050, and to eliminate the use of fossil fuels altogether by 2100, have raised several questions.

Are these objectives feasible? Are they consistent with national commitments? Are they sufficient to stabilize the global climate without dangerous rates of warming? And are they anything new?

Media are important. Especially the media we trust. One might express the effect of a piece of journalism (J) about, say, a particular drug or food, as a factor of media authority (A), multiplied by the size of audience (D), divided by the availability of credible alternative sources (S).

The more of the latter which are accessible to the audience, and thus the greater the challenge to the “truthiness” of (J), the lesser the impact on individual and collective behavior. Where people trust the news source, and the issue is complex, and alternative analyses are not easily sourced, the effect is greater.

Ever wonder how much it costs to develop a new drug? The independent, non-profit research group, The Tufts Center for the Study of Drug Development, estimates US$2.6 billion, almost double the centre’s previous estimate a decade ago. But how accurate is this figure?